Retour aux résultats
Articles (2020), Value in Health, 23 (8), pp. 985-993

The Value of a QLY for France: a new approach to propose acceptable reference values

TÉHARD Bertrand, DETOURNAY Bruno, BORGET Isabelle, ROZE Stéphane, PUYOU DE POUVOURVILLE Gérard

France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France. Lien vers l'article

TÉHARD, B., DETOURNAY, B., BORGET, I., ROZE, S. and PUYOU DE POUVOURVILLE, G. (2020). The Value of a QLY for France: a new approach to propose acceptable reference values. Value in Health, 23(8), pp. 985-993.

Mots clés : #drug-pricing, #cost, #effectiveness, #France, #health, #economic-assessment, #incremental-cost, #effectiveness-ratio, #preference, #based-value